We are live on
!
Find out more
DC
Decheng Capital Portfolio holdings
AUM
$661M
1-Year Est. Return
299.97%
This Fund
S&P 500
This Quarter
Est. Return
-10.08%
1 Year Est. Return
+299.97%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$466M
AUM Growth
+$44M
(+10%)
Cap. Flow
+$133M
Cap. Flow
% of AUM
28.46%
Top 10 Holdings %
Top 10 Hldgs %
83.67%
Holding
30
New
4
Increased
10
Reduced
5
Closed
2
Top Buys
| 1 |
UPB
Upstream Bio Inc
UPB
|
+$73.4M |
| 2 |
CG Oncology
CGON
|
+$30.5M |
| 3 |
Lyell Immunopharma
LYEL
|
+$11.8M |
| 4 |
Revolution Medicines
RVMD
|
+$11.3M |
| 5 |
Aclaris Therapeutics
ACRS
|
+$5.64M |
Top Sells
| 1 |
Phathom Pharmaceuticals
PHAT
|
+$6.88M |
| 2 |
GeneDx Holdings
WGS
|
+$4.4M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$2.52M |
| 4 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
+$1.88M |
| 5 |
Arcus Biosciences
RCUS
|
+$996K |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$6.44B
| $183M | 39.2% |
6,371,669
+892,859
| +16% | +$30.5M |
|
2
Nuvation Bio
NUVB
$2.05B
| $69M | 14.81% |
25,954,439
| – | – |
|
|
UPB
3
Upstream Bio Inc
UPB
$396M
| $54M | 11.58% |
+3,285,293
| New | +$73.4M |
|
4
NewAmsterdam Pharma
NAMS
$3.74B
| $19.8M | 4.24% |
770,000
+180,000
| +31% | +$3.82M |
|
5
Illumina
ILMN
$28.3B
| $12.7M | 2.72% |
94,767
| – | – |
|
|
6
Arcus Biosciences
RCUS
$3.52B
| $12M | 2.58% |
808,789
-61,001
| -7% | -$996K |
|
7
Krystal Biotech
KRYS
$10.3B
| $12M | 2.58% |
76,772
+5,000
| +7% | +$887K |
|
|
8
Revolution Medicines
RVMD
$39.2B
| $9.89M | 2.12% |
226,000
+224,000
| +11,200% | +$11.3M |
|
9
MoonLake Immunotherapeutics
MLTX
$1.67B
| $9.29M | 1.99% |
171,600
+5,000
| +3% | +$255K |
|
10
Crinetics Pharmaceuticals
CRNX
$8.88B
| $8.59M | 1.84% |
167,958
+10,000
| +6% | +$559K |
|
11
BeyondSpring
BYSI
$52.2M
| $7.96M | 1.71% |
4,882,651
-75,492
| -2% | -$149K |
|
|
MRUS
12
DELISTED
Merus
MRUS
| $7.95M | 1.71% |
189,098
| – | – |
|
|
13
Lyell Immunopharma
LYEL
$349M
| $7.62M | 1.63% |
+595,467
| New | +$11.8M |
|
|
14
Zentalis Pharmaceuticals
ZNTL
$340M
| $7.08M | 1.52% |
2,338,095
-770,000
| -25% | -$2.52M |
|
|
ACLX
15
DELISTED
Arcellx
ACLX
| $6.47M | 1.39% |
84,377
+63,200
| +298% | +$5.46M |
|
|
16
Phathom Pharmaceuticals
PHAT
$881M
| $5.64M | 1.21% |
694,254
-555,746
| -44% | -$6.88M |
|
|
17
Aclaris Therapeutics
ACRS
$782M
| $5.62M | 1.21% |
+2,266,667
| New | +$5.64M |
|
18
Legend Biotech
LEGN
$4.46B
| $5M | 1.07% |
153,558
+45,000
| +41% | +$1.86M |
|
19
Cytokinetics
CYTK
$11.2B
| $4.7M | 1.01% |
100,000
+5,957
| +6% | +$309K |
|
20
BioNTech
BNTX
$23.3B
| $4.56M | 0.98% |
+40,000
| New | +$4.56M |
|
21
Aura Biosciences
AURA
$725M
| $4.24M | 0.91% |
515,555
| – | – |
|
22
Equillium
EQ
$166M
| $3.33M | 0.71% |
4,447,308
| – | – |
|
23
4D Molecular Therapeutics
FDMT
$611M
| $2.23M | 0.48% |
400,000
+2,165
| +0.5% | +$17K |
|
24
Vera Therapeutics
VERA
$3.05B
| $2.1M | 0.45% |
49,767
-20,000
| -29% | -$886K |
|
25
AtriCure
ATRC
$1.75B
| $819K | 0.18% |
26,797
| – | – |
|
Similar funds
TPM
AWA
FAM
OL
GC
HIG
RCG
AWM